iVeena
Salt Lake City, Utah, United States · Biotechnology, Health Care · 8 employees
iVeena Delivery Systems, Inc. is a privately held, clinical stage ophthalmology company developing disease-modifying pharmacologic innovations for refractive diseases. iVeena has licensed its lead asset to Glaukos Corporation, IVMED-80, an Orphan Drug Designated eye drop for keratoconus. iVeena is developing IVMED-85, a first in class, investigational eye drop formulation for pediatric myopia.
Funding history
- Grant — $2.0M — Sep 2025
- Series B — $3.0M — Feb 2025
- Venture - Series Unknown — $2.1M — Jul 2020
- Venture - Series Unknown — Undisclosed — Dec 2017
- Venture - Series Unknown — $2.1M — Dec 2016
Recent signals
- Feb 04, 2026: iVeena Delivery Systems Promotes Michael Burr to COO and Sarah Molokhia to CSO
- Sep 18, 2025: Raised $2.0M in Grant
- Feb 05, 2025: Raised $3.0M in Series B
- Jul 08, 2020: Raised $2.1M in Venture - Series Unknown
- Dec 04, 2017: Raised Undisclosed in Venture - Series Unknown
- Dec 08, 2016: Raised $2.1M in Venture - Series Unknown
See plans & pricing → Track iVeena’s funding, hiring, and signals — with verified contacts — on Fundz.